Back to top

pharmaceuticals: Archive

Zacks Equity Research

Horizon (HZNP) Up on Initial Talks of Buyout by Pharma Giants

Horizon (HZNP) holds preliminary discussions with Amgen, Sanofi and Janssen, a subsidiary of J&J, seeking an offer for its acquisition by any one of the pharma giants. Shares rise.

SNYNegative Net Change JNJNegative Net Change AMGNNegative Net Change HZNPPositive Net Change

Zacks Equity Research

AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal

The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.

AZNPositive Net Change MRKNegative Net Change GILDPositive Net Change VRTXNegative Net Change

Zacks Equity Research

CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug

CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.

BIIBPositive Net Change GILDPositive Net Change SLDBNegative Net Change CINCNegative Net Change

Zacks Equity Research

Gilead (GILD), RCUS Announce Positive Data From NSCLC Study

Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).

BIIBPositive Net Change GILDPositive Net Change SLDBNegative Net Change RCUSPositive Net Change

Zacks Equity Research

Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA

Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.

BIIBPositive Net Change GILDPositive Net Change SPPINegative Net Change SLDBNegative Net Change

Zacks Equity Research

Here's What's Driving AbbVie's (ABBV) Outperformance This Year

AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

RHHBYNegative Net Change JNJNegative Net Change ABBVNegative Net Change GMABPositive Net Change

Zacks Equity Research

Incyte (INCY) Outperforms YTD: Will the Momentum Continue?

Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.

NVSPositive Net Change LLYNegative Net Change INCYPositive Net Change SNDXPositive Net Change

Zacks Equity Research

Regeneron (REGN) Outperforms YTD: What's in Store for 2023?

Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.

REGNNegative Net Change SNYNegative Net Change BAYRYNegative Net Change

Kinjel Shah

Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication

Merck (MRK) offers to buy Imago Biosciences (IMGO). The European Commission approves AbbVie's (ABBV) immunology medicine, Skyrizi for Crohn's disease.

GSKNegative Net Change MRKNegative Net Change ABBVNegative Net Change IMGONegative Net Change

Zacks Equity Research

Novartis (NVS) Set to Advance Malaria Drug Into Phase III

Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.

NVSPositive Net Change BIIBPositive Net Change RHHBYNegative Net Change MRKNegative Net Change

Zacks Equity Research

AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease

AbbVie's (ABBV) Skyrizi becomes the first specific IL-23 inhibitor to get approval for Crohn's disease in the European Union.

MRKNegative Net Change GILDPositive Net Change VRTXNegative Net Change ABBVNegative Net Change

Zacks Equity Research

Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.

AVEONegative Net Change ETONPositive Net Change IMCRPositive Net Change PALINegative Net Change

Zacks Equity Research

Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update

Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.

REGNNegative Net Change CTMXPositive Net Change APLSNegative Net Change INMPositive Net Change

Zacks Equity Research

Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal

Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.

BMYNegative Net Change MRKNegative Net Change VRTXNegative Net Change ANGNNegative Net Change

Zacks Equity Research

GSK to Withdraw Blenrep From U.S. Market on FDA Request

GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.

GSKNegative Net Change MRKNegative Net Change GILDPositive Net Change VRTXNegative Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights AbbVie PepsiCo, The Walt Disney, Caterpillar and PBF Energy

AbbVie, PepsiCo, The Walt Disney, Caterpillar and PBF Energy are part of The Zacks top Analyst Blog.

CATNegative Net Change PEPNegative Net Change DISNegative Net Change ABBVNegative Net Change PBFNegative Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co

Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co are part of the Zacks top Analyst Blog.

XOMNegative Net Change MRKNegative Net Change ADMNegative Net Change MCKNegative Net Change MPCNegative Net Change

Sheraz Mian

Top Stock Reports for AbbVie, PepsiCo & Walt Disney

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), PepsiCo, Inc. (PEP) and The Walt Disney Company (DIS).

CATNegative Net Change BKNegative Net Change AFLNegative Net Change PEPNegative Net Change DISNegative Net Change ABBVNegative Net Change

Zacks Equity Research

bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.

AVEONegative Net Change BLUENegative Net Change ETONPositive Net Change IMCRPositive Net Change

Nalak Das

Buy These 5 Corporate Giants Flying High in Disappointing 2022

We have narrowed our search to five U.S. corporate behemoths that have popped year to date. These are: ADM, MPC, XOM, MRK and MCK.

XOMNegative Net Change MRKNegative Net Change ADMNegative Net Change MCKNegative Net Change MPCNegative Net Change

Zacks Equity Research

AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag

The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.

MRKNegative Net Change VRTXNegative Net Change ABBVNegative Net Change GMABPositive Net Change

Zacks Equity Research

Bristol Myers (BMY) Gains 24.2% YTD: What's in Store for 2023?

Biotech giant Bristol Myers (BMY) outperforms the industry and the S&P 500 Index as Eliquis and Opdivo maintain momentum despite generic competition for Revlimid.

BMYNegative Net Change LLYNegative Net Change GILDPositive Net Change

Zacks Equity Research

Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option

Jazz Pharma (JAZZ) gets FDA approval for an MWF intramuscular (IM) dosing schedule for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.

JAZZPositive Net Change ESPRPositive Net Change ZYMENegative Net Change ASRTNo Net Change

Zacks Equity Research

Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters

Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.

PFENegative Net Change MRKNegative Net Change MRNANegative Net Change BNTXPositive Net Change

Zacks Equity Research

Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?

Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.

GSKNegative Net Change GILDPositive Net Change PBYINegative Net Change SNDXPositive Net Change